942947-95-7

Basic information

• Product Name: 2-Amino-5-bromo-4-chloro-3-nitropyridine
• Synonyms: 2-Amino-5-bromo-4-chloro-3-nitropyridine;5-Bromo-4-chloro-3-nitro-2-pyridinamine;5-bromo-4-chloro-3-nitropyridin-2-amine;2-AMino-5-broMo-4-chloro-...;5-Bromo-4-chloro-3-nitro-pyridin-2-ylamine
• CAS NO: 942947-95-7
• Molecular Formula: C₅H₃BrClN₃O₂
• Molecular Weight: 252.45
• Product Categories: API intermediates;Heterocycle-Pyridine series
• Mol File: 942947-95-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 338.37 °C at 760 mmHg
• Flash Point: 158.441 °C
• Appearance: /
• Density: 2.020
• Refractive Index: 1.689
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -0.88±0.50(Predicted)
• CAS DataBase Reference: 2-Amino-5-bromo-4-chloro-3-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-5-bromo-4-chloro-3-nitropyridine(942947-95-7)
• EPA Substance Registry System: 2-Amino-5-bromo-4-chloro-3-nitropyridine(942947-95-7)

Safety Data

• Hazardous Substances Data: 942947-95-7(Hazardous Substances Data)

Usage

General Description

2-Amino-5-bromo-4-chloro-3-nitropyridine is a chemical compound with the molecular formula C5H3BrClN3O2. It is a yellow crystalline solid that is mainly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 2-Amino-5-bromo-4-chloro-3-nitropyridine is known for its strong nitro and bromo substituents, which make it a valuable building block in the production of various drugs and pesticides. However, it is also important to note that 2-Amino-5-bromo-4-chloro-3-nitropyridine is a potentially hazardous compound and should be handled with care due to its toxic and irritant properties.

InChI:InChI=1/C5H3BrClN3O2/c6-2-1-9-5(8)4(3(2)7)10(11)12/h1H,(H2,8,9)

Upstream product

• 942947-94-6 5-bromo-4-chloro-pyridin-2-ylamine 
• 6980-08-1 4-chloro-3-nitro-2-pyridinamine 
• 19798-80-2 2-Amino-4-chloropyridine 

Downstream Products

• 942948-37-0 5-bromo-4-(4-(4-chlorobenzyl)piperazin-1-yl)-3-nitropyridin-2-amine 
• 942948-84-7 5-bromo-3-nitro-4-(4-phenylpiperazin-1-yl)pyridin-2-amine 
• 942948-39-2 5-bromo-3-nitro-4-(4-(pyridin-3-ylmethyl)piperazin-1-yl)pyridin-2-amine 
• 942950-28-9 5-bromo-4-(4-(4-fluorobenzyl)piperazin-1-yl)-3-nitropyridin-2-amine 
• 942949-20-4 5-bromo-3-nitro-4-[4-(1-phenyl-ethyl)-piperazin-1-yl]-pyridin-2-ylamine 
• 1131604-99-3 C₅H₅BrClN₃ 
• 942949-00-0 5-bromo-3-nitro-4-(4-(1-(pyridin-4-yl)ethyl)piperazin-1-yl)pyridin-2-amine 
• 942948-58-5 1-(4-(2-amino-5-bromo-3-nitropyridin-4-yl)piperazin-1-yl)-2-phenoxyethanone 
• 942948-50-7 5-bromo-4-(4-(4-fluorobenzyl)-1,4-diazepan-1-yl)-3-nitropyridin-2-amine 
• 942948-23-4 2-(4-(2-amino-5-bromo-3-nitropyridin-4-yl)piperazin-1-yl)-N-phenylacetamide 

Relevant articles and documents

SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted 1 H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

Discovery and analgesic evaluation of 8-chloro-1,4-dihydropyrido[2,3- b ]pyrazine-2,3-dione as a novel potent d -amino acid oxidase inhibitor

A series of 5-azaquinoxaline-2,3-dione derivatives were synthesized and evaluated on d-amino acid oxidase (DAAO) inhibition as potential α-hydroxylactam-based inhibitors. The potent inhibitory activities in vitro suggested that 5-nitrogen could significantly enhance the binding affinity by strengthening relevant hydrogen bond interactions. The analgesic effects of intrathecal and systemic injection of 8-chloro-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione, a representative molecule of 5-azaquinoxaline-2,3-dione, were investigated in rodents. This research not only confirmed the analgesic effect of the DAAO inhibitors but provided a new class of chemical entities with oral application potential for the treatment of chronic pain and morphine analgesic tolerance.

Optimization of imidazo[4,5- b ]pyridine-based kinase inhibitors: Identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia

Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin- 1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A Kd = 7.5 nM, Aurora-B K d = 48 nM), FLT3 kinase (Kd = 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd = 38 nM) and FLT3(D835Y) (Kd = 14 nM). FLT3-ITD causes constitutive FLT3 kinase activation and is detected in 20-35% of adults and 15% of children with acute myeloid leukemia (AML), conferring a poor prognosis in both age groups. In an in vivo setting, 27e strongly inhibited the growth of a FLT3-ITD-positive AML human tumor xenograft (MV4-11) following oral administration, with in vivo biomarker modulation and plasma free drug exposures consistent with dual FLT3 and Aurora kinase inhibition. Compound 27e, an orally bioavailable dual FLT3 and Aurora kinase inhibitor, was selected as a preclinical development candidate for the treatment of human malignancies, in particular AML, in adults and children.